Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse

Clinical Prostate Cancer

Volumn 3, Issue 3, 2004, Pages 174-181

  Pucar, Darko ^a   Koutcher, Jason A ^a   Shah, Ankoor ^a   Dyke, John P ^b   Schwartz, Lawrence ^a   Thaler, Howard ^a   Kurhanewicz, John ^c   Scardino, Peter T ^a   Kelly, W Kevin ^a   Hricak, Hedvig ^a   Zakian, Kristen L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Radiation therapy; Radical prostatectomy

Indexed keywords

CARBOPLATIN; ESTRAMUSTINE; GOSERELIN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTION; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 19944418214     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2004.n.028     Document Type: Article

References (35)

1. Kurhanewicz J, Vigneron DB, Hricak H, et al. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996; 198:795-805.
2. Kurhanewicz J, Vigneron DB, Males RG, et al. The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am 2000; 38:115-138, viii-ix.
3. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 1999; 213:473-480.
4. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164:400-404.
5. Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002; 223:91-97.
6. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step section pathology after radical prostatectomy. Radiology; in Press.
7. Vigneron DB, Males R, Noworolski S, et al. 3D MRSI of prostate cancer: correlation with histologic grade. Presented at: Sixth Scientific Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine; April 18-24, 1998; Sydney, Australia.
8. Zakian KL, Sircar K, Kleinman S, et al. Correlation of proton MR spectroscopic imaging with gleason score based on step section radical prostatectomy. Presented at: 2002 Annual Meeting of the Radiological Society of North America; December 1-6, 2002; Chicago, IL.
9. Bostwick DG, Graham SD Jr, Napalkov P, et al. Staging of early prostate cancer: a proposed tumor volume-based prognostic index. Urology 1993; 41:403-411.
10. Christensen WN, Partin AW, Walsh PC, et al. Pathologic findings in clinical stage A2 prostate cancer. Relation of tumor volume, grade, and location to pathologic stage. Cancer 1990; 65:1021-1027.
11. Stamey TA, McNeal JE, Freiha FS, et al. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988; 139:1235-1241.
12. Yu KK, Scheidler J, Hricak H, et al. Prostate Cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999; 213:481-488.
13. Partin AW, Pound CR, Clemens JQ, et al. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993; 20:713-725.
14. Lerner SE, Blute ML, Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 1995; 154:1447-1452.
15. Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer 1993; 72:1709-1725.
16. D'Amico AV, Moul, JV, Kattan, MW. Emerging prognostic factors for outcome prediction in clinically localized prostate cancer: prostate-specific antigen level, race, molecular markers and neural neworks. In: Vogelzang NJ, Scardino, PT, Shipley WU, Coffey DS, eds. Genitourinary Oncology. Philadelphia: Lippincott Williams & Wilkins, 2000:681-697.
17. Zeitman AL, Edelstein RA, Coen JJ, et al. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease free outcome. Urology 1994; 43:828-833.
18. van den Ouden D, Hop WC, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998; 160:1392-1397.
19. Konety BR, Eastham JA, Reuter VE, et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 2004; 171:709-713.
20. Males R, Vigneron D, Star-Lack J, et al. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2000; 43:17-22.
21. Nelson SJ, Day MR, Carvajal L. Methods for analysis of serial volume MRI and 1H MRS data for the assessment of response to therapy in patients with brain tumors. Presented at: Third Annual Meeting of the International Society of Magnetic Resonance in Medicine, Nice, France, 1995. Vol. 2.
22. Star-Lack J, Nelson SJ, Kurhanewicz J, et al. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 1997; 38:311-321.
23. Nelson SJ, Huhn S, Vigneron DB, et al. Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: presentation of a detailed case study. J Magn Reson Imaging 1997; 7:1146-1152.
24. Bottomley PA. Selective volume method for performing localized NMR spectroscopy. U.S. patent no 4480228. 1984.
25. Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167:528-534.
26. Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 2003; 61:14-24.
27. Kattan MW, Fearn PA, Leibel S, et al. The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48:1469-1474.
28. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90:766-771.
29. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277:1445-1451.
30. McNeal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol 1992; 23:258-266.
31. Sausville EA, Longo DL. Principles of cancer treatment. In: Braunwald E, Fauci AS, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine. Vol I. New York: McGraw Hill, 2001:530-546.
32. Abi-Aad AS, Macfarlane MT, Stein A, et al. Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J Urol 1992; 147:952-955.
33. Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994; 152:1826-1830.
34. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-1597.
35. Mettlin CJ, Murphy GP, Rosenthal DS, et al. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83:1679-1684.